Teramed Ariba
This article was originally published in The Gray Sheet
Executive Summary
European launch of the abdominal aortic aneurysm endovascular stent-graft commences following CE mark clearance in August, the firm announces Oct. 4. U.S. trials are underway. The device will compete in an estimated $200 mil. worldwide AAA market, which is expected to grow to more than $1 bil. within the next seven years (1"The Gray Sheet" June 18, 2001, p. 23)